These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31207358)

  • 21. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
    Arrieta A; Page TF; Veledar E; Nasir K
    PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV; Cokkinos P; Kolovou G
    Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract]   [Full Text] [Related]  

  • 35. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 38. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
    Navar AM; Mulder HM; Wojdyla DM; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006019. PubMed ID: 31918581
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.